Skip to main content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Ophthalmology 1/2017

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

BMC Ophthalmology > Ausgabe 1/2017
Joel Hanhart, Doron S. Comaneshter, Yossi Freier Dror, Shlomo Vinker



The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD.


We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables.


During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54–1.84), P < .001.


We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Ophthalmology 1/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

10.02.2021 | Katarakt | Leitthema | Ausgabe 3/2021

Therapie der postoperativen Endophthalmitis

Operieren oder nur injizieren?

08.02.2021 | Vaskulitiden | Übersichten | Ausgabe 3/2021 Open Access

Intraokulare Entzündungen bei Brolucizumab-Anwendung

Patientenmanagement – Diagnose – Therapie

28.01.2021 | themenschwerpunkt | Ausgabe 1/2021 Open Access

Fünfzig Jahre Schielbehandlung – Ein Erfahrungsbericht aus Klinik und Praxis

26.01.2021 | themenschwerpunkt | Ausgabe 1/2021

MISS (minimalinvasive Schielchirurgie) zur Strabismuskorrektur